You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Medications Articles
Popular Medications Articles
Highly Recommended Medications Articles
Send a link to this page to your friends and colleagues.
DepoMed of Menlo Park, California, reported a second set of positive phase I data for its oral anti-diabetic drug Metformin GR. Data from a five-day trial enrolling 14 healthy volunteers suggest that 1000 mg of Metformin GR once per day is as well-tolerated as two doses per day of 500 mg Glucophage.
Metformin GR, an extend-release product, is still in its development stage. It is designed to provide an alternative to Bristol-Myers Squibb's leading diabetes drug Glucophage, which requires twice-daily dosing.
Glucophage is scheduled to lose its patent this month.
Metformin GR is formulated using the company's Gastric Retention (GR) delivery technology. Using normal physiological processes where the stomach retains large objects for further digestion, the GR System swells following ingestion and is retained in the stomach for a number of hours. Once in the stomach, the drug is released at a controlled rate.
A larger phase II trial of Metformin GR is scheduled to begin in the third quarter.
0 comments - Sep 1, 2000
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.